Human T cell lymphotropic virus-associated leukemia/lymphoma
- PMID: 16093798
- PMCID: PMC2652726
- DOI: 10.1097/01.cco.0000174037.84903.fb
Human T cell lymphotropic virus-associated leukemia/lymphoma
Abstract
Purpose of review: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options.
Recent findings: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition.
Summary: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
References
-
- Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664–672. This is an excellent recent review of treatment for ATLL. - PubMed
-
- Kannagi M, Harashima N, Kurihara K, et al. Adult T-cell leukemia: future pro-phylaxis and immunotherapy. Expert Rev Anticancer Ther. 2004;4:369–376. - PubMed
-
- Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res. 2003;89:69–132. - PubMed
-
- Jeang K-T, Giam C-Z, Majone F, Aboud M. Life, death, and Tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem. 2004;279:31991–31994. This is an excellent review of the Tax oncoprotein. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
